STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMNM
  4. [Form 4] Immunome Inc. Insider Trading Activity

Immunome (IMNM) director Barchas sells 83,464 shares under 10b5-1 plans

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Immunome Inc. director Isaac Barchas reported three open-market sales of common stock totaling 83,464 shares in August 2026. On August 12, he directly sold 11,048 shares at $27.25 per share, leaving 92,211 shares held directly. On August 10 and 11, entities associated with him, including ABHMC II LLC, sold 10,125 and 62,291 shares, respectively; he disclaims beneficial ownership of those shares except for any pecuniary interest. All reported sales occurred automatically under Rule 10b5-1 trading plans adopted on March 31, 2026.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Barchas Isaac
Role Director
Sold 83,464 shs ($2.20M)
Type Security Shares Price Value
Sale Common Stock F5 11,048 $27.25 $301K
Sale Common Stock F1, F4, F3 62,291 $26.23 $1.63M
Sale Common Stock F1, F2, F3 10,125 $26.07 $264K
Holdings After Transaction: Common Stock — 0 shares (Indirect, See footnote); Common Stock — 92,211 shares (Direct)
Footnotes (5)
  1. F1. The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.
  2. F2. The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  3. F3. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
  4. F4. The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  5. F5. The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026.
Total shares sold 83,464 shares Aggregate common stock sales reported across three transactions in August 2026
Direct sale on 2026-08-12 11,048 shares at $27.25 per share Open-market sale of Immunome common stock by Isaac Barchas
Indirect sale on 2026-08-11 62,291 shares at $26.23 weighted average Indirect open-market sale with prices from $26.00 to $26.48 per share
Indirect sale on 2026-08-10 10,125 shares at $26.07 weighted average Indirect open-market sale with prices from $26.005 to $26.14 per share
Shares held after direct sale 92,211 shares Direct Immunome common stock holdings reported following the 2026-08-12 transaction
Rule 10b5-1 trading plan regulatory
"The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The weighted average sale price for the transaction report was $26.07"
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest in such shares, if any"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did Immunome (IMNM) disclose in this Form 4?
Immunome (IMNM) disclosed that director Isaac Barchas reported three open-market sales of common stock totaling 83,464 shares in August 2026, including both direct holdings and shares held through an affiliated entity.

How many Immunome (IMNM) shares did Isaac Barchas sell directly and at what price?
On August 12, 2026, Isaac Barchas directly sold 11,048 shares of Immunome common stock at a price of $27.25 per share, and reported 92,211 shares remaining in his direct ownership afterward.

Were the Immunome (IMNM) insider sales made under a Rule 10b5-1 plan?
Yes. All reported sales occurred automatically under Rule 10b5-1 trading plans adopted on March 31, 2026, one by ABHMC II LLC and one by Isaac Barchas, according to the footnotes.

What indirect Immunome (IMNM) share sales were reported for entities linked to Isaac Barchas?
Entities associated with Isaac Barchas, including AMBHMC II LLC, reported selling 10,125 shares on August 10, 2026 and 62,291 shares on August 11, 2026, in open-market transactions described as indirect ownership.

Does Isaac Barchas claim beneficial ownership of all indirectly sold Immunome (IMNM) shares?
No. For shares held by ABHMC II LLC, Barchas disclaims beneficial ownership except to the extent of any pecuniary interest, despite having voting and investment power via his role and power of attorney.

What price information was given for Immunome (IMNM) insider sales on August 10 and 11, 2026?
For August 10, the weighted average sale price was $26.07 with trades from $26.005–$26.14. For August 11, the weighted average sale price was $26.23 with trades from $26.00–$26.48, as disclosed in the footnotes.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Barchas Isaac
(Last)(First)(Middle)
C/O IMMUNOME, INC.
18702 N. CREEK PARKWAY, SUITE 100
(Street)
BOTHELL WASHINGTON 98011
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/10/2026S(1)10,125D$26.07(2)62,291ISee footnote(3)
Common Stock08/11/2026S(1)62,291D$26.23(4)0ISee footnote(3)
Common Stock08/12/2026S(5)11,048D$27.2592,211D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.
2. The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
4. The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
5. The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026.
/s/ Sandra Stoneman, Attorney-in-Fact08/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR